BioSpace News Archive

Major advancements in medical science and technology, coupled with the increasing adoption of personalized medicine initiatives are likely to aid in expansion of the global DNA & RNA banking services market during the forecast period set between 2020 and 2030.

XPhyto Therapeutics Corp., and its exclusive German diagnostics development partner, 3a-diagnostics GmbH, are pleased to announce that all actions and procedures required for its European regulatory application for the rapid point-of-care SARS-CoV-2 RT-PCR Test System have been completed.

Cytovia Therapeutics, Inc.and Cellectis announced that they have entered into a strategic research and development collaboration to develop TALEN® gene-edited iPSC NK and CAR-NK cells.

Method utilizes electronic sensor that instantly and accurately detects concentrations of the antipsychotic drug, clozapine, in the blood via a finger prick, allowing maximal therapeutic benefit while minimizing side effects

Lexaria Bioscience’s drug delivery technology, DehydraTECHTM improves the “bioavailability” of pharmaceutical ingredients.

Axonics Modulation Technologies, Inc., a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, has received PMA supplement approval from the U.S. Food & Drug Administration for its third-generation implantable neurostimulator.

Akan Biosciences, LLC, a Maryland based, clinical stage biotech company innovating cellular technology and proprietary manufacturing methods to produce stem cell-based therapeutics, announced that the U.S. Food and Drug Administration has accepted the Investigational New Drug Application for StroMel™, its lead candidate for the treatment of Osteoarthritis of Knee.

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that the company has partnered with Chicago Public Schools to provide antigen and Droplet Digital PCR ™ testing for Chicago Public School teachers and staff.

Upcoming study by TMRR on the global cryogenic PPE market intends to offer 360-degree analysis of the key factors driving or limiting overall market growth throughout the assessment period of 2020 to 2030.

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, announces that it has received the first data for its SARS-CoV-2 rapid antigen test from ongoing clinical studies in Europe and the UK.